CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Surgery
Link
http://link.springer.com/content/pdf/10.1007/s00595-009-4328-7.pdf
Reference29 articles.
1. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 2008;109:491–501.
2. Ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527–532.
3. Eisenhauer EA, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 1995;31ASuppl 4:S11–S13.
4. Ravdin PM. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin Oncol 1997;24:S10-18–S10-21.
5. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58–65.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Resistance to Combined Anthracycline–Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas;International Journal of Molecular Sciences;2024-01-15
2. Effects of Curcumin Treatment on Cell Energy Status, Levels of Mitochondrial Enzymes, and Gene Expression of Glucose-related Mechanism in Pancreatic Cancer Cell Lines;Journal of Basic and Clinical Health Sciences;2023-09-30
3. Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy;Drug Metabolism and Disposition;2023-02-02
4. Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance;Cancers;2021-04-09
5. Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells;Pharmaceuticals;2021-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3